Agency
Larkin Community Hospital INC
Larkin Community Hospital INC was paid $2.30M by Medicaid between Jan 2018 and Nov 2024, across 127 billing codes. Its largest line is G0410, Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes — 27% of everything it billed.
33Billing provider infoLARKIN COMMUNITY HOSPITAL INC
MIAMI, FL 33143
MIAMI, FL 33143
33aNPI1952311243assigned 08/09/2006
33bProvider typeCase Management Agency
28Total paid$2.30M
24GClaims121,494
24DCodes billed127
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Case Management Agency providers in Florida
Rank by total paid#116 of 357
Median peer was paid$839K
This provider vs. median2.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,144 | $605K | |
| 2019 | 27,523 | $653K | |
| 2020 | 24,982 | $269K | |
| 2021 | 23,210 | $292K | |
| 2022 | 16,081 | $334K | |
| 2023 | 3,943 | $118K | |
| 2024incomplete | 1,611 | $27K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | 27% | 12,503 | 799 | $615K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 18% | 4,303 | 168 | $408K |
| G0378 | Hospital observation service, per hour | 11% | 3,339 | 2,090 | $251K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 9.1% | 9,786 | 5,108 | $209K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.5% | 2,985 | 2,074 | $171K |
| 80053 | Comprehensive metabolic panel | 3.6% | 9,508 | 3,723 | $82K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 1,681 | 1,086 | $74K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 2.8% | 686 | 486 | $63K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.4% | 1,659 | 1,154 | $56K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 1,167 | 768 | $48K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.7% | 5,235 | 2,774 | $39K |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 1.2% | 363 | 271 | $28K |
115 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 2,274 | $26K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 719 | $24K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 374 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,466 | $17K |
| 82947 | <1% | 4,470 | $16K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 765 | $14K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 182 | $9K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 473 | $9K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,333 | $7K |
| 86769 | <1% | 402 | $7K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,696 | $7K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 880 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,614 | $5K |
| 97161 | <1% | 444 | $5K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 252 | $4K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,679 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,797 | $4K |
| 83735 | <1% | 379 | $4K | |
| 84100 | <1% | 384 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,284 | $4K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 216 | $4K |
| 85730 | <1% | 1,251 | $4K | |
| 85610 | <1% | 1,319 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 780 | $4K |
| 81001 | <1% | 2,172 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 570 | $3K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 508 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 787 | $3K |
| 81003 | <1% | 2,384 | $3K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 76 | $2K |
| 82550 | <1% | 3,496 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 21 | $2K |
| 99284 | Emergency room visit (serious) | <1% | 364 | $2K |
| 84484 | <1% | 373 | $1K | |
| 97165 | <1% | 118 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 550 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 33 | $1K |
| 83550 | <1% | 19 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 205 | $932.28 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 508 | $924.21 |
| 85652 | <1% | 830 | $771.71 | |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | <1% | 37 | $739.70 |
| 76770 | <1% | 287 | $618.74 | |
| 84703 | <1% | 612 | $610.23 | |
| 74018 | <1% | 386 | $568.85 | |
| 96367 | <1% | 92 | $485.75 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 186 | $485.64 |
| 87088 | <1% | 862 | $464.34 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 93 | $388.43 |
| 76641 | <1% | 178 | $387.49 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 815 | $376.91 |
| 80164 | <1% | 399 | $332.02 | |
| 71250 | <1% | 287 | $323.59 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 55 | $319.63 |
| 83690 | <1% | 69 | $286.75 | |
| 82150 | <1% | 68 | $286.75 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 324 | $284.46 |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 144 | $204.14 |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 155 | $201.54 |
| 0011A | <1% | 40 | $200.00 | |
| 0012A | <1% | 19 | $200.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 224 | $189.18 |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 54 | $155.08 |
| 72100 | <1% | 208 | $149.30 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 59 | $148.77 |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 112 | $148.77 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 59 | $148.77 |
| 83605 | <1% | 57 | $148.36 | |
| 87075 | <1% | 91 | $126.87 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 154 | $118.04 |
| 87040 | <1% | 82 | $104.74 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 46 | $90.15 |
| 82607 | <1% | 131 | $65.11 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 543 | $60.66 |
| 72040 | <1% | 55 | $52.94 | |
| 82140 | <1% | 85 | $51.50 | |
| 82746 | <1% | 76 | $51.50 | |
| 73030 | <1% | 80 | $44.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 89 | $40.63 |
| 87186 | <1% | 131 | $40.55 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 66 | $32.39 |
| 80320 | <1% | 365 | $28.94 | |
| G1007 | Clinical decision support mechanism aim specialty health, as defined by the medicare appropriate use criteria program | <1% | 16 | $24.81 |
| 73565 | <1% | 23 | $22.00 | |
| 76830 | Ultrasound, transvaginal | <1% | 18 | $22.00 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 25 | $17.91 |
| 83880 | <1% | 45 | $15.40 | |
| 76536 | <1% | 28 | $14.91 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 57 | $7.59 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 345 | $5.04 |
| 87205 | <1% | 86 | $1.26 | |
| 80076 | 0% | 18 | $0.00 | |
| 93970 | 0% | 80 | $0.00 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 0% | 22 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 44 | $0.00 |
| 93880 | 0% | 25 | $0.00 | |
| 77080 | 0% | 405 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 36 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 94 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 57 | $0.00 |
| 83540 | 0% | 23 | $0.00 | |
| 93925 | 0% | 23 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 69 | $0.00 |
| J3490 | Unclassified drugs | 0% | 61 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 122 | $0.00 |
| 90686 | 0% | 17 | $0.00 | |
| 73521 | 0% | 23 | $0.00 | |
| 85379 | 0% | 27 | $0.00 | |
| 82728 | 0% | 23 | $0.00 | |
| 94760 | 0% | 23 | $0.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 25 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 28 | $0.00 |
| 88342 | 0% | 19 | $0.00 | |
| 82553 | 0% | 31 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMICHEL, JACK (CEO)
| Provider | Location | Paid |
|---|---|---|
| Oracle Health Systems INC | South Miami, FL | $363K |
| Project Access Foundation INC | Hialeah, FL | $221K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.